Commercialization of an intravenous hemostatic nanoparticle for bleeding management
Official title: Commercialization Strategy for an Intravenous Hemostatic Nanotechnology for Bleeding Management
Funded at Haima Therapeutics, LLC · NIH-11313383 · Data updated 2026-11-12
A new nanoparticle-based treatment called SynthoPlate could help stop dangerous bleeding across many situations, from accidents to surgeries, by mimicking how natural platelets work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Haima Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 18, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $499,999 |
| NIH project number | 1SB1HL184353-01 |
| Project ID | NIH-11313383 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients at risk of life-threatening bleeding due to trauma, surgery, childbirth, or bleeding disorders who may benefit from rapid hemostasis.
✕Less likely to help
Patients whose bleeding is not due to acute trauma or who may have reactions to nanoparticle therapies, or those not eligible for the product’s mechanism of action.
What this research studies
This project aims to bring SynthoPlate, a platelet-inspired nanoparticle, toward practical use for stopping bleeding quickly and widely. The work focuses on developing a scalable, cost-effective formulation and commercialization path to help patients who experience life-threatening bleeding. The team will address regulatory, manufacturing, and clinical considerations to move toward real-world use. If successful, this effort could lead to a new option that reduces dependence on donor blood products and traditional coagulation factors.
Why it matters
Potential benefit: If successful, patients with severe bleeding could receive faster, broader, and potentially safer hemostatic treatment.
How similar studies have gone: Previous nanoparticle-based hemostatic approaches have shown promise in preclinical or early-stage studies, with ongoing development in the field.
Where this research is happening
-
Haima Therapeutics, LLC
Cleveland, United States Active
Researchers
- Principal investigator: Bruckman, Michael Arthur — Haima Therapeutics, LLC
- Study coordinator: Bruckman, Michael Arthur
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.